Stallergenes Greer's Delisting To Focus Leadership On Facility Issues
The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.
You may also be interested in...
A leading allergy company in Canada has been snapped up by Stallergenes Greer, targeting North America as part of a renewed business development strategy.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer are helping to fund a public-private partnership aimed at improving the primary care health infrastructure in Africa; the collaboration will also exploit the companies’ experience providing therapies and using digital and web-enabled technologies.